Enlivex Doses First Patient In A Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM In Up To 46 Patients With Thumb Osteoarthritis
Portfolio Pulse from Benzinga Newsdesk
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has dosed the first patient in a Phase I/II trial for AllocetraTM, targeting thumb osteoarthritis. This trial aims to evaluate the safety and efficacy of AllocetraTM in up to 46 patients, with no current FDA-approved therapies for this condition.
June 24, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enlivex Therapeutics Ltd. has initiated a Phase I/II trial for AllocetraTM in thumb osteoarthritis, a condition with no current FDA-approved therapies. The trial will assess safety and efficacy in up to 46 patients.
The initiation of a Phase I/II trial for AllocetraTM in a condition with no current FDA-approved therapies is a significant milestone for Enlivex. Positive trial results could lead to a new treatment option and potentially boost the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100